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Abstract
Background: The oral mucosa has an important role in maintaining barrier integrity at the gateway to the
gastrointestinal and respiratory tracts. Smoking is a strong environmental risk factor for the common oral
inflammatory disease periodontitis and oral cancer. Cigarette smoke affects gene methylation and expression
in various tissues. This is the first epigenome-wide association study (EWAS) that aimed to identify biologically
active methylation marks of the oral masticatory mucosa that are associated with smoking.
Results: Ex vivo biopsies of 18 current smokers and 21 never smokers were analysed with the Infinium Methylation
EPICBeadChip and combined with whole transcriptome RNA sequencing (RNA-Seq; 16 mio reads per sample) of the
same samples. We analysed the associations of CpG methylation values with cigarette smoking and smoke pack year
(SPY) levels in an analysis of covariance (ANCOVA). Nine CpGs were significantly associated with smoking status, with
three CpGs mapping to the genetic region of CYP1B1 (cytochrome P450 family 1 subfamily B member 1; best
p = 5.5 × 10−8) and two mapping to AHRR (aryl-hydrocarbon receptor repressor; best p = 5.9 × 10−9). In the SPY
analysis, 61 CpG sites at 52 loci showed significant associations of the quantity of smoking with changes in
methylation values. Here, the most significant association located to the gene CYP1B1, with p = 4.0 × 10−10.
RNA-Seq data showed significantly increased expression of CYP1B1 in smokers compared to non-smokers (p =
2.2 × 10−14), together with 13 significantly upregulated transcripts. Six transcripts were significantly
downregulated. No differential expression was observed for AHRR. In vitro studies with gingival fibroblasts
showed that cigarette smoke extract directly upregulated the expression of CYP1B1.
Conclusion: This study validated the established role of CYP1B1 and AHRR in xenobiotic metabolism of tobacco smoke
and highlights the importance of epigenetic regulation for these genes. For the first time, we give evidence of this role
for the oral masticatory mucosa.
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Background
Smoking is considered one of the most important envir-
onmental factors causing premature death by promoting a
variety of malignant and non-malignant diseases. It in-
creases the relative risk of dying by up to 2.8 and shortens
lifetime expectancies by 10 years on average [1]. The oral
mucosa is the barrier tissue that is most directly exposed
to cigarette smoke. Accordingly, smoking is a strong risk
factor for a variety of oral diseases such as oral cancer [2]
and the widespread common oral inflammatory disease
periodontitis (PD) [3]. The deleterious effects of smoking
on tissue integrity are driven by a variety of biological
mechanisms. In the recent past, evidence grew that some
of these mechanisms correlate with changes in DNA
methylation patterns. DNA methylation plays a particular
role in cell differentiation and the maintenance of cell spe-
cificity [4] and represents an important mechanism for
cells to react on persistent external stimuli, allowing som-
atic cells to adjust gene expression to a particular environ-
ment in a long-term manner that can be passed on to
daughter cells [5, 6]. Smoking is currently the best studied
environmental factor altering DNA-methylation patterns
[7]. A plethora of studies exist that show significantly dif-
ferent methylation patterns in smokers compared to non-
smokers in different tissues [2, 8–22] and in the context of
smoke-related diseases like cancer [23] or chronic ob-
structive pulmonary disease (COPD) [21]. The best-
replicated gene-specific association of differential methyla-
tion with smoking is attributed to the aryl-hydrocarbon
receptor repressor AHRR across various tissues and cell
types [8, 10, 12–14, 16, 17, 20, 22, 24, 25]. AHRR is a core
regulator in the aryl hydrocarbon receptor (AhR) signal-
ling cascade, modulating dioxin toxicity pathways involv-
ing Cytochrome P450, most likely in a cell-specific
manner [26]. Most EWAS that assessed the role of CpG
methylation in tobacco-related xenobiotic metabolism
analysed leukocytes, but some also analysed airway epithe-
lial cells [27] and buccal cells [12, 21, 22]. These cell types
are located at the interface to the environment and form a
mechanical and physiological barrier. Most notably, a
large comprehensive EWAS analysed buccal cells of 790
healthy individuals and identified a set of 1501 CpGs that
were differentially methylated in smokers [22]. Buccal
swabs largely consist of non-keratinized squamous epithe-
lial cells detached from the inner facial cheeks, and im-
mune cells from the saliva. In the current study, we chose
to analyse the effects of cigarette smoke on the healthy
keratinized oral mucosa, which is restricted to the gingiva,
the tongue and the hard palate. It is the tissue that forms
the mechanical barrier between the oral cavity and the
hard tissues (alveolar bone and skull). It consists of an
upper layer of highly keratinized stratified squamous epi-
thelium, the underlying keratinized connective tissue and
invaded immune cells, which make it a strong mechanical
and immunological barrier against injuries and pathogens.
In addition, the gingiva is the only interface of the human
body that is penetrated by hard tissues (the teeth), forming
a direct connection between the environment and the
bone. In this context, the masticatory mucosa is unique.
Accordingly, the gingiva is the tissue which is affected by
the common inflammatory disease periodontitis, for
which smoking is the strongest risk factor. In contrast,
buccal cells are not involved in the pathophysiology of
periodontitis. The different functions of the lining mucosa
of the inner cheeks, where buccal cells are derived, and of
the masticatory mucosa are characterised by pronounced
differences in cell turnover [28], cellular differentiation
[29], and differences in expression patterns and perme-
ability [29, 30]. Because of these special features in cell
derivation, function and clinical significance, the objective
of our study was to assess the putative differences of
methylation and transcription of the oral masticatory mu-
cosa between healthy smokers and never smokers. Know-
ledge of these differences will provide information on the
regulatory responses of this interface to direct exposure to
xenobiotics of tobacco smoke before periodontitis or oral
cancer becomes a clinical manifestation, and if defective,
may have a relevant role in the disease aetiology.
To this end, we performed an EWAS with 39 healthy
participants, all of them showing no signs of oral inflam-
mation as indicated by a periodontal screening index
(PSI) < 2. Taking into account that the masticatory mu-
cosa itself also differs in cell type composition across dif-
ferent oral regions [31], samples were extracted from a
clearly defined site. In this very homogeneous set of ex
vivo biopsies, methylation patterns were investigated
using the Infinium Methylation EPICBeadChip. In order
to investigate potential effects of differentially methyl-
ated CpG sites on gene expression, we additionally per-
formed RNA-sequencing (RNA-Seq) in the same
samples. With this study, we provide a genome-wide
methylation reference set and a RNA-Sequencing data
set for the healthy masticatory mucosa, the clinically af-
fected tissue in periodontitis. For the first time,
smoking-informed reference datasets for methylation
and expression patterns are combined for the oral mu-
cosa. With these datasets, we were able to validate asso-
ciations of CpGs with smoking levels shown in buccal
swabs [22] and add to the knowledge of potential tissue-
specific differential methylation in smokers. We showed
shifts in transcriptional patterns of smokers, which
partly paralleled the differential methylation patterns.
Results
DNA methylation differences of the masticatory mucosa
between smokers and non-smokers
The DNA of 18 healthy smokers and 21 healthy non-
smokers of the same age was analyzed with the Infinium
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DNA MethylationEPIC BeadChip (Table 1). Next, 802,
254 DNA methylation probes that passed the QC cri-
teria were investigated for statistical significant differ-
ences in methylation levels between smokers and never
smokers in an ANCOVA adjusting for age, sex and
batch effects. A QQ plot revealed some global inflation
of the test statistics as compared to the expected distri-
bution, with an inflation factor of λ = 1.12 (Fig. 1a). After
correction for multiple testing, we found nine CpGs to
be significantly hypomethylated in smokers, with
cg04066994 in the AHRR (aryl-hydrogen receptor re-
pressor) gene showing the strongest association (p =
5.9 × 10−10, Δβ = − 0.08 in smokers; Fig. 1b, Table 2). The
overall effect sizes of differentially methylated loci in
smokers are illustrated in Fig. 2. Additionally, two sig-
nificant CpGs mapped to the intronic region of CYP1B1
and another one to an intergenic region 24 kb upstream
of CYP1B1, three mapped to the long noncoding RNA
LINC00673 and one was located in an intergenic region
~ 6 kb upstream of CYP1A2 (cytochrome P450 family 1
subfamily A member 2). Observed effect sizes were
highest in CYP1B1, with Δβ = − 0.18 for cg02162897
(p = 5.5 × 10−8).
Subsequently, the methylation levels were analysed for
association with smoke pack-years (SPY), a measure for
smoking intensity that includes information of the quan-
tity of smoking. After correction for multiple testing, 54
CpGs showed significant hypomethylation and seven
CpGs showed significant hypermethylation with increas-
ing smoking levels, measured as SPY (q < 0.05; Figs. 3 and
4 and Table 3). The most significant differential methyla-
tion was observed in the 3′ untranslated region (3′UTR)
of the gene CYP1B1 (cytochrome P450 family 1 subfamily
B member 1), with an average change in methylation of
Δβ = − 0.046 per ten SPY at cg01584760 (p = 4.0 × 10−10;
q = 3.2 × 10−4). Additionally, four other CpGs in the in-
tronic region of CYP1B1 showed significant hypomethyla-
tion with increasing SPY (e.g. cg20408276, Δβ = − 0.108
per ten SPY, p = 1.1 × 10−7). Another three significant
probes (q < 0.05) flanked the long noncoding antisense
RNA CYP1B1-AS1, which is partially overlapping with
CYP1B1 (e.g. cg10090109, Δβ = − 0.015 per ten SPY, p =
2.1 × 10−8). Among the other significant probes (q < 0.05),
six showed similar or higher effect sizes compared to
those observed at CYP1B1. These mapped to the genes
PIP4K2A (phosphatidylinositol-5-phosphate 4-kinase type
2 alpha; cg02030592, Δβ = − 0.106 per ten SPY, p = 5.3 ×
10−7), DLX5 (distal-less homeobox 5; e.g. cg11891395,
Δβ = − 0.097 per ten SPY, p = 2.5 × 10−6), FABP4 (fatty acid
binding protein 4; cg07234508, Δβ = − 0.073 per ten SPY,
p = 1.1 × 10− 6), FABP5P3 (fatty acid binding protein 5
pseudogene 3; cg16171205, Δβ = − 0.047 per ten SPY, p =
6.4 × 10−7) and C10orf46 (cg27009448, Δβ = − 0.046 per
ten SPY, p = 3.0 × 10−6). To account for our small sample
size, which was very susceptible to false negative findings,
we relaxed the significance threshold to q < 0.15 and com-
pared the results of the SPY analysis to previously pub-
lished results from a well-powered EWAS on smoking in
buccal cells [22] and to a set of CpGs that was reported to
be associated with smoking by multiple independent
EWAS performed in blood [32]. Out of 352 CpGs that
passed the lowered significance threshold in our data, 33
mapped to 18 loci that were associated in buccal cells,
three of which were also reported in blood, among them
AHRR (Table 4, Additional file 1). Moreover, two CpGs
were associated with q < 0.15 that mapped to loci associ-
ated in blood, but not in buccal cells.
Estimation of different cell type fractions in the
masticatory mucosa
The masticatory mucosa consists of a layer of kerati-
nized epithelium, an underlying layer of connective tis-
sue and invaded immune cells. We calculated the
fraction of different cell types with the EpiDISH algo-
rithm. The number of fibroblasts and immune cells in
our samples was moderate (median 0.15 and 0.16, re-
spectively) compared to epithelial cells (median 0.69;
Fig. 5a, Additional file 2). The amount of epithelial cells
in smokers and never smokers was highly similar (me-
dian 0.69 and 0.68, respectively). Similarly, we observed
no differences in the estimated fractions of fibroblasts
and immune cells, which seemed to be very slightly re-
duced in smokers (median of 0.15 and 0.14, respectively,
compared to 0.16 for both cell types in never smokers).
Differential gene expression between smokers and never
smokers in the masticatory mucosa
We performed RNA-Seq of the same samples that were
used in the EWAS to quantify the gene expression in
the masticatory mucosa. Among the ten highest
expressed genes in the solid oral mucosa, six were kera-
tin genes (KRT1, KRT6A, KRT10, KRT14, KRT16 and
KRT76 with median TPM values between 118,399 and
355,686; Additional file 3). The other genes of the top
ten highest expressed genes were S100A8 and S100A9 of
the S100 protein family, which has a prominent role in
the regulation of inflammatory processes and immune
response, COX1 (cytochrome c oxidase subunit 1) and
EEF1A1 (elongation factor 1-alpha 1).
Table 1 Basic characteristics of the EWAS study population
Smokers (n = 18) Never smokers (n = 21)
Sex (males) 10 (55.6%) 8 (38.1%)
Age, years (mean) 38 ± 11 35 ± 11
SPY in smokers (mean) 12 ± 11 NA
SPY≥ 10 9 (50%) NA
SPY 2 > 10 9 (50%) NA
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After adjustment for multiple testing according to Benja-
mini & Hochberg, 20 genes showed differential expression
between smokers and never smokers (Table 5). The most
significant association of differential expression and smok-
ing status was found for CYP1B1 (p = 2.2 × 10−14, q = 4.9 ×
10−10, log2 fold change = 2.9). A KEGG pathway analysis
showed a significant upregulation of two pathways, the Me-
tabolism of Xenobiotics by Cytochrome P450 Pathway,
(KEGG entry: rn00980; p = 3.7 × 10−4; q = 0.034; Table 6)
and the Aminoacyl-tRNA biosynthesis pathway (KEGG
entry: hsa00970; p = 1.9 × 10−4; q = 0.034). A Reactome
pathway analysis showed 24 pathways to be significantly
upregulated in smokers (q < 0.05). Out of these, 14 path-
ways belonged to the pathway classes of “cell cycle
function” and/or “DNA replication” and three to the path-
way class “metabolism” with respect to electron transport,
most notably the top significant pathway involving the Cit-
ric Acid Cycle and Respiratory Electron Transport (Reac-
tome identifier: R-HSA-1428517; p = 1.4 × 10−5; q = 0.009).
In both approaches, no significantly downregulated path-
ways were found (Additional file 4).
We next investigated whether changes in methylation
patterns have a measurable effect on gene expression in
vivo. At a significance threshold of FDR = 0.05, CYP1B1
was the only gene that showed correlation of hypome-
thylation with gene expression. Considering the limited
statistical power of our sample that made it susceptible
for false negative associations, we relaxed the significant
Fig. 1 Manhattan and QQ plots for epigenome-wide associations with smoking status in the masticatory mucosa. a The QQ plot showed some
evidence of inflated association signals (λ = 1.12). b Manhattan plot showing -log10 transformed p values from the ANCOVA plotted against the
genomic location of the probes. The horizontal lines indicate the nominal significance threshold (p < 0.05) and the genome-wide significance
threshold (p < 10-7)
Table 2 Change in DNA methylation β values for smokers compared to never smokers
CpG identifier Chr Position in bp (hg19a) Gene symbol Region Δβ p valueb q value
cg02162897 2 38,300,537 CYP1B1c Body − 0.183 5.5 × 10−8 0.022
cg20408276 2 38,300,586 CYP1B1c Body − 0.176 3.6 × 10−7 0.040
cg24752487 2 38,324,188 21 kb upstream of CYP1B1c Intergenic; Mammalian H3K27me3-
repression mark
− 0.138 2.1 × 10−7 0.040
cg06036945 5 394,869 AHRRc Body − 0.125 3.7 × 10−7 0.040
cg04066994 5 394,891 AHRRc Body − 0.083 5.9 × 10−10 4.7 × 10−4
cg20385913 15 75,054,510 6 kb downstream of CYP1A2 intergenic − 0.063 3.1 × 10−7 0.040
cg02123605 17 70,497,550 LINC00673c Body − 0.056 4.0 × 10−7 0.040
cg23167235 17 70,532,667 LINC00673c Body − 0.018 4.7 × 10−7 0.042
cg23398508 17 70,536,199 LINC00673c Body − 0.098 1.1 × 10−7 0.030
Shown are results for all CpGs significant after correction for multiple testing (q < 0.05). For comparison, we additionally included the results from the SPY analysis
for significant CpGs
aNCBI build GRCh37
bp values are from the analysis of covariance (ANCOVA) with adjustment by age, sex and batch. Chr chromosome, bp basepairs, SPY smoke pack years,
kb kilobasepairs
cGenetic region previously reported to be associated with smoking in buccals [22]
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thresholds and correlated all CpGs with q < 0.15 to those
genes that were differentially expressed in smokers with
a nominal p value of < 0.05. This analysis suggested dif-
ferential expression of 15 genes with 25 CpGs at q < 0.15
(Additional file 5). To balance the resulting increased
risk of type I errors, we subsequently included only
those genes that mapped to at least two associated CpGs
(q < 0.15) in our EWAS and had previously been re-
ported to be associated with smoking in buccal swabs or
blood [22, 32]. In total, four genes fulfilled these criteria:
Fig. 2 Volcano plot showing methylation differences of smokers compared to never smokers against -log10 of p values from the ANCOVA.
Identifiers are given for the CpGs that were significantly associated with smoking after adjustment for multiple testing
Fig. 3 Manhattan and QQ pots for epigenome-wide associations with SPY in the masticatory mucosa. a The QQ plot showed some evidence for
inflation of association signals (λ = 1.09). b Manhattan plot showing -log10 transformed p values from the ANCOVA plotted against the genomic
location of the probes. The horizontal lines indicate the nominal significance threshold (p < 0.05) and the genome-wide significance
threshold (p < 10-7)
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CYP1B1, SLC7A5 (solute carrier family 7 member 5),
EDC3 (enhancer of mRNA decapping 3) and LAMA3
(laminin subunit alpha 3), the latter of which showed
opposite effect sizes for differential expression and
differential methylation (Table 7). Because the differen-
tially methylated lncRNA CYP1B1-AS1 was not covered
by our RNA-Seq reads, we analysed the expression by
qRT-PCR in 69 individuals (n = 32 smokers, 37 never
smokers). CYP1B1-AS1 was stronger expressed in
smokers when compared to never smokers with
p = 0.0061.
In vitro effects of cigarette smoke extract on the
expression of hypomethylated genes in primary gingival
fibroblasts
CYP1B1 had been shown to be induced in response to
cigarette smoke exposure in the adenocarcinomic hu-
man alveolar basal epithelial cell line A549 from cancer-
ous lung tissue [23]. To validate the regulatory effect of
tobacco smoke on CYP1B1 gene expression for gingival
cells, we exposed gingival fibroblasts to cigarette smoke
extract (CSE) in vitro. Exposure to CSE significantly in-
creased the mRNA levels of CYP1B1 and of the corre-
sponding antisense RNA CYP1B1-AS with p = 0.019 and
p = 0.023, respectively (Fig. 6).
Association of smoking-induced changes in methylation
levels in oral squamous cell carcinoma
To investigate a potential role of smoking-induced
CYP1B1 and AHRR hypomethylation in the development
of oral cancer, we compared the methylation data from
our healthy never smokers with the TCGA data for 16
oral squamous cell carcinoma (OSCC) biopsies that were
specified as “gum” or “palate”, similar to the samples
used in our EWAS. As the exact extraction site was not
specified for OSCC samples, we first investigated cell
type compositions using EpiDISH in this potentially het-
erogeneous tissue source. The cell composition varied
extremely among OSCC samples, irrespective of smok-
ing status (Fig. 5b, Additional file 2), with an overall
higher amount of epithelial cells compared to our EWAS
never smokers (median of 0.80 in OSCC compared to
0.69 in our samples). The OSCC data are based on the
450k array, and of a total of 202 CpGs at the genetic re-
gion of AHRR and CYP1B1 that were analysed in our
EPIC array dataset, 36% (n = 72) were not analysed with
the 450k array. Yet, a total of 130 CpGs at AHRR (n = 98
CpGs) and CYP1B1 (n = 32 CpGs) were shared between
the OSCC samples and our data. In the OSCC data, at
CYP1B1, 1 CpG was significantly hypomethylated and
16 CpG were significantly hypermethylated (corrected
Fig. 4 Volcano plot showing methylation differences per 10 SPY against -log10 of p values from the ANCOVA. Identifiers are given for the CpGs
that were significantly associated with an increase in smoking after adjustment for multiple testing
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Table 3 Change in DNA methylation β values per ten smoking pack years for significant CpGs
CpG identifier Chr Position in bp (hg19a) Gene symbol Region Δβ per 10 SPY p valueb q value
cg09741074 1 1,310,496 AURKAIP1 5′UTR, 1st Exon − 0.002 8.2 × 10−7 3.5 × 10−2
cg27290274 1 15,386,739 KIAA1026c Body 0.003 1.2 × 10−6 3.9 × 10−2
cg22112416 1 161,124,001 UFC1 Body − 0.003 2.7 × 10−6 4.1 × 10−2
cg12522303 1 207,818,368 CR1L TSS200 0.009 2.8 × 10−6 4.2 × 10−2
cg14686555 2 6,121,915 LOC400940 TSS200 0.005 2.1 × 10−6 4.1 × 10−2
cg08502446 2 36,891,478 Intergenic − 0.017 3.5 × 10−6 4.6 × 10−2
cg01584760 2 38,296,474 CYP1B1c,d 3′UTR − 0.046 4.0 × 10−10 3.2 × 10−4
cg02162897 2 38,300,537 CYP1B1c,d Body − 0.110 1.1 × 10−7 1.3 × 10−2
cg20408276 2 38,300,586 CYP1B1c,d Body − 0.108 1.1 × 10−7 1.3 × 10−2
cg00565882 2 38,300,707 CYP1B1c,d Body − 0.041 1.7 × 10−6 4.1 × 10−2
cg01410359 2 38,302,230 CYP1B1c,d Body − 0.037 3.6 × 10−6 4.6 × 10−2
cg26818476 2 38,337,733 CYP1B1-AS Upstream − 0.021 2.3 × 10−6 4.1 × 10−2
cg10090109 2 38,338,120 CYP1B1-AS Upstream − 0.015 2.1 × 10−8 5.9 × 10−3
cg17498874 2 38,460,564 CYP1B1-AS Downstream − 0.062 1.1 × 10−6 3.9 × 10−2
cg04192580 2 223,726,348 ACSL3 5′UTR − 0.008 1.3 × 10−6 4.0 × 10−2
cg24985459 3 37,035,090 MLH1 TSS200, 1st Exon − 0.001 2.5 × 10−6 4.1 × 10−2
cg02748316 3 50,273,710 GNAI2 5′UTR − 0.002 2.5 × 10−6 4.1 × 10−2
cg04859961 3 131,951,282 CPNE4; tRNACys Body 0.024 2.6 × 10−6 4.1 × 10−2
cg11344771 3 188,108,786 LPP 5′UTR − 0.020 6.5 × 10−7 3.1 × 10−2
cg26094150 5 79,378,871 THBS4 Body − 0.003 2.9 × 10−7 2.2 × 10−2
cg24179483 5 170,814,656 NPM1 TSS200 − 0.002 3.1 × 10−6 4.3 × 10−2
cg09575472 5 174,045,109 Intergenic − 0.032 2.0 × 10−6 4.1 × 10−2
cg07471462 6 33,168,624 SLC39A7 1stExon, 5′UTR − 0.002 1.8 × 10−6 4.1 × 10−2
cg13273398 6 116,937,346 RSPH4A TSS1500 − 0.018 2.7 × 10−6 4.1 × 10−2
cg26902259 6 126,102,246 NCOA7 TSS200 − 0.008 2.6 × 10−6 4.1 × 10−2
cg02363875 7 960,707 ADAP1 TSS200 0.003 1.7 × 10−6 4.1 × 10−2
cg18526602 7 6,487,739 DAGLB TSS200 − 0.002 2.0 × 10−6 4.1 × 10−2
cg20231669 7 22,862,119 TOMM7 Body − 0.005 9.2 × 10−8 1.3 × 10−2
cg01858449 7 33,551,455 BBS9 Body − 0.020 6.2 × 10−7 3.1 × 10−2
cg27032146 7 96,652,115 DLX5c Body − 0.062 2.4 × 10−6 4.1 × 10−2
cg11891395 7 96,652,153 DLX5c Body − 0.097 2.5 × 10−6 4.1 × 10−2
cg21757062 7 121,376,168 329 bp from 7SK Intergenic − 0.027 1.5 × 10−6 4.1 × 10−2
cg00924357 7 131,012,552 MKLN1 Body − 0.001 2.6 × 10−6 4.1 × 10−2
cg16171205 7 152,135,221 FABP5P3 Body − 0.047 3.0 × 10−7 2.2 × 10−2
cg15821835 8 67,686,767 SGK3 TSS1500 − 0.006 2.3 × 10−6 4.1 × 10−2
cg07234508 8 82,395,948 FABP4 TSS1500 − 0.073 1.1 × 10−6 3.9 × 10−2
cg15845333 8 144,417,025 TOP1MT 1stExon − 0.003 1.6 × 10−7 1.6 × 10−2
cg14519682 9 130,213,309 LRSAM1 TSS1500 − 0.002 8.0 × 10−7 3.5 × 10−2
cg02030592 10 22,863,044 PIP4K2A Body − 0.106 5.3 × 10−7 3.1 × 10−2
cg09823091 10 94,644,717 EXOC6 Body −0.033 1.8 × 10−7 1.6 × 10−2
cg08206898 10 116,581,183 FAM160B1 TSS1500 − 0.016 2.2 × 10−6 4.1 × 10−2
cg27009448 10 120,492,138 C10orf46 Body − 0.046 3.0 × 10−6 4.3 × 10−2
cg12106634 11 108,092,400 ATM TSS1500 − 0.006 1.2 × 10−6 3.9 × 10−2
cg06531661 12 57,522,120 LRP1 TSS200 −0.002 1.1 × 10−7 1.3 × 10−2
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for multiple testing, n = 130 tests). At AHRR, 30 CpGs
were significantly hypomethylated and 22 CpGs were
significantly hypermethylated. The effect sizes in OSCC
were high, with Δβ = − 0.48 for cg12202185 in AHRR
(p = 2.8 × 10−7), and Δβ = 0.45 for cg09799983 in
CYP1B1 (p = 7.5 × 10−12), which both were not associ-
ated with smoking in our samples (Additional file 6). In
our EWAS, five CpGs within CYP1B1 showed significant
hypermethylation in smokers, two of which were not
analysed on the 450k chip for OSCC. The remaining
three were significantly hypermethylated in OSCC, with
the highest effect size at cg02162897 with Δβ = 0.197
(p = 4.7 × 10−6, Table 8). For AHRR, two CpGs were sig-
nificantly associated in our EWAS but were not covered
by the 450k chip used for the OSCC data. This is why
we investigated the CpGs that flanked our associated
CpGs in the EWAS, albeit these were not associated in
our EWAS. In OSCC, one of these adjacent CpGs,
cg04551776, showed a significant hypermethylation
(Δβ = 0.15, p = 2.7 × 10−5).
Discussion
In the current EWAS, we generated a reference dataset
for combined differential gene methylation and expres-
sion patterns of the healthy masticatory mucosa of never
smokers and smokers, accompanied by corresponding
estimations of cell type fractions. We identified 63 sig-
nificant differentially methylated CpGs after adjustment
for multiple testing. Of these, the differential methyla-
tion at the gene CYP1B1 had the highest effect size, with
11% hypomethylation per ten SPY. CYP1B1 is a member
of the cytochrome P450 gene family, and the gene prod-
uct is involved in detoxification of pro-carcinogens in to-
bacco smoke [33]. CYP1B1 was previously reported to
be hypomethylated with epigenome-wide significance in
EWAS of buccal swabs [22] and small airway epithelial
cells of healthy smokers [27]. The significantly associated
genes PIP4K2A and DLX5 showed similar effect sizes as
CYP1B1. Interestingly, the GWAS catalogue reports an
association with variants within PIP4K2A for several
cancer types. For DLX5, which was also found to be sig-
nificantly associated with SPY in buccal cells [22], the
GWAS catalogue reports variants associated with bone
mineral densities and facial morphology. There is sub-
stantial evidence that smokers suffer from lower bone
mineral densities [34, 35], possibly due to increased bone
resorption [36]. Smoke-related toxins were described as
inducing bone loss mediated by the AhR-pathway in-
volving CYP1A1, CYP1A2 and CYP1B1 in mice [37].
Interestingly, in the analysis of smokers against never
smokers as a categorical value, we found nine CpGs to
be significantly differentially methylated, with the top
Table 3 Change in DNA methylation β values per ten smoking pack years for significant CpGs (Continued)
CpG identifier Chr Position in bp (hg19a) Gene symbol Region Δβ per 10 SPY p valueb q value
cg13016115 14 23,388,406 RBM23 TSS200 − 0.002 1.3 × 10−6 4.0 × 10−2
cg24151229 14 93,260,858 GOLGA5 5’UTR − 0.002 3.6 × 10−6 4.6 × 10−2
cg15377113 14 93,799,418 BTBD7c TSS200 − 0.001 3.1 × 10−6 4.3 × 10−2
cg12361883 14 104,313,596 LINC00637 TSS1500 − 0.002 6.4 × 10−7 3.1 × 10−2
cg26693173 15 33,137,114 FMN1 Body − 0.015 2.2 × 10−8 5.9 × 10−3
cg09167084 15 40,861,240 RPUSD2 TSS1500 − 0.008 1.1 × 10−6 3.9 × 10−2
cg04928180 15 99,791,525 LRRC28 TSS200 − 0.001 2.3 × 10−6 4.1 × 10−2
cg07984365 16 739,425 WDR24 1stExon 0.011 2.5 × 10−6 4.1 × 10−2
cg21737024 16 30,441,289 DCTPP1 1stExon − 0.003 3.8 × 10−7 2.6 × 10−2
cg12642651 17 9,861,712 GAS7 Body − 0.022 3.6 × 10−6 4.6 × 10−2
cg13167372 17 70,536,814 LINC00673c,d Gene body 0.027 2.2 × 10−6 4.1 × 10−2
cg12182124 18 21,451,563 LAMA3c TSS1500 − 0.040 2.2 × 10−6 4.1 × 10−2
cg16113793 18 21,451,607 LAMA3c TSS1500 − 0.028 1.8 × 10−6 4.1 × 10−2
cg19328682 18 47,807,700 MBD1 5’UTR − 0.004 6.1 × 10−7 3.1 × 10−2
cg27308982 18 77,196,450 NFATC1 Body, 5’UTR − 0.012 1.1 × 10−6 3.9 × 10−2
cg02693125 20 23,401,585 NAPB Body − 0.006 1.9 × 10−6 4.1 × 10−2
cg18411827 22 23,412,613 GNAZ TSS200 − 0.003 1.4 × 10−6 4.0 × 10−2
Shown are results for all CpGs significant after correction for multiple testing (q < 0.05)
aNCBI build GRCh37
bp values are from the analysis of covariance (ANCOVA) with SPY as a continuous variable and adjustment by age, sex and batch. Chr chromosome, bp basepairs,
SPY smoke pack years
cGenetic region previously reported to be associated with smoking in buccals [22]
dShared association with the analysis of smoking status
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Table 4 Change in DNA methylation β values per ten smoking pack years for validated CpGs from the literature
CpG identifier Chr Position in bp (hg19a) Gene symbol Δβ per 10 SPY p valueb q value
Associations in buccals and blood
cg04066994c 5 394,891 AHRR − 0.04 8.2 × 10−6 0.07
cg14389122d 15 74,945,851 EDC3 − 0.05 1.3 × 10−5 0.08
cg17181940c 15 74,948,075 EDC3 − 0.05 5.6 × 10−6 0.06
Associations in buccals
cg05223638 1 3,036,168 PRDM16 − 0.02 5.6 × 10−5 0.14
cg27290274 1 15,386,739 KIAA1026 0.00 1.2 × 10−6 0.04
cg01584760c 2 38,296,474 CYP1B1 − 0.05 3.8 × 10−10 3.2 × 10−4
cg02162897d 2 38,300,537 CYP1B1 − 0.11 1.2 × 10−7 0.01
cg20408276d 2 38,300,586 CYP1B1 − 0.11 1.1 × 10−7 0.01
cg00565882d 2 38,300,707 CYP1B1 − 0.04 1.7 × 10−6 0.04
cg01410359 2 38,302,230 CYP1B1 − 0.04 3.4 × 10−6 0.05
cg03890222 2 38,302,487 CYP1B1 − 0.02 6.2 × 10−5 0.15
cg21715189d 2 38,304,802 CYP1B1 − 0.06 3.2 × 10−5 0.11
cg06722870 2 236,840,187 AGAP1 0.00 6.0 × 10−5 0.14
cg04578109c 4 169,475,207 PALLD − 0.01 1.5 × 10−5 0.08
cg21490342 6 31,852,301 EHMT2 0.01 6.5 × 10−5 0.15
cg23076086 6 112,194,849 FYN − 0.01 2.1 × 10−5 0.09
cg18873386 7 96,651,915 DLX5 − 0.06 3.4 × 10−5 0.11
cg11367354 7 96,651,983 DLX5 − 0.05 1.1 × 10−5 0.07
cg27032146 7 96,652,115 DLX5 − 0.06 2.4 × 10−6 0.04
cg11500797 7 96,652,123 DLX5 − 0.07 7.1 × 10−6 0.06
cg11891395 7 96,652,153 DLX5 − 0.10 2.3 × 10−6 0.04
cg03532926 7 153,584,839 DPP6 0.01 1.3 × 10−5 0.08
cg06324554 7 157,495,841 PTPRN2 − 0.06 4.9 × 10−5 0.13
cg02583494c 9 97,640,188 C9orf3 − 0.03 4.2 × 10−5 0.12
cg22754866 10 99,771,121 CRTAC1 − 0.03 8.5 × 10−6 0.07
cg15377113 14 93,799,418 BTBD7 0.00 3.0 × 10−6 0.04
cg12344004 15 89,877,906 POLG − 0.01 4.1 × 10−5 0.12
cg10099957 16 87,869,757 SLC7A5 − 0.06 9.6 × 10−6 0.07
cg09285525 16 87,869,786 SLC7A5 − 0.06 1.3 × 10−5 0.08
cg27555036 16 87,898,191 SLC7A5 − 0.03 4.5 × 10−5 0.13
cg13167372d 17 70,536,814 LINC00673 0.03 3.4 × 10−6 0.05
cg12182124 18 21,451,563 LAMA3 − 0.04 1.9 × 10−6 0.04
cg16113793 18 21,451,607 LAMA3 − 0.03 1.5 × 10−6 0.04
Associations in blood
cg06566772c 10 63,661,030 ARID5B 0.00 1.7 × 10−5 0.09
cg16611234d 11 58,870,075 ~ 4.5 kb from FAM111B − 0.03 3.9 × 10−5 0.12
Shown are results for all CpGs that map to genes previously reported in a large EWAS on buccal swabs [22] or in a systematic review on EWAS on blood [32] and
which were associated with SPY in our EWAS with q < 0.15
aNCBI build GRCh37
bp values are from the analysis of covariance (ANCOVA) with adjustment by age, sex and batch. Chr chromosome, bp basepairs, kb kilobasepairs, SPY smoke
pack years
cAuxiliary probe on EPIC chip
dSame CpG reported in previous EWAS
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Fig. 5 Cell type estimations in the masticatory mucosa inferred by EpiDISH. Shown are the boxplots of the average weight proportions of the
major cell types epithelial cells (Epi), fibroblasts (Fib) and immune cells (IC) for EWAS (a) and OSCC samples (b). a EpiDISH estimations for the
complete EWAS sample set (smokers and never smokers, n = 39) and for the subsets smokers (n = 18) and never smokers (n = 21). b EpiDISH
estimations for the complete set of analysed OSCC samples (smokers and non-smokers, n = 16) and for the subsets smokers (n = 7) and
non-smokers (n = 9)
Table 5 Differentially expressed transcripts in smokers compared to never smokers
Ensembl gene Gene symbol log2 fold change p value q value
ENSG00000138061 CYP1B1a 2.9 2.2 × 10−14 4.9 × 10−10
ENSG00000181019 NQO1 1.2 1.2 × 10−10 1.3 × 10−6
ENSG00000176153 GPX2 1.0 1.0 × 10−9 7.7 × 10−6
ENSG00000108602 ALDH3A1 0.9 3.6 × 10−9 2.0 × 10−5
ENSG00000140465 CYP1A1a 4.6 2.7 × 10−8 1.2 × 10−4
ENSG00000278270 RPS9 2.3 3.1 × 10− 7 0.0012
ENSG00000164236 ANKRD33B − 0.7 6.2 × 10−7 0.0019
ENSG00000167165 UGT1A6 0.8 1.8 × 10−6 0.0042
ENSG00000171403 KRT9 1.3 1.9 × 10−6 0.0042
ENSG00000180574 EIF2S3B − 3.2 1.7 × 10−6 0.0042
ENSG00000244122 UGT1A7 1.6 3.0 × 10−6 0.0060
ENSG00000197641 SERPINB13 0.6 3.7 × 10−6 0.0068
ENSG00000267023 5.2 7.4 × 10−6 0.0126
ENSG00000124588 NQO2 0.4 1.1 × 10−5 0.0179
ENSG00000117009 KMO 2.9 1.6 × 10−5 0.0226
ENSG00000118322 ATP10B 0.5 1.6 × 10−5 0.0226
ENSG00000284292 − 2.8 2.6 × 10−5 0.0335
ENSG00000135766 EGLN1 − 0.3 3.0 × 10−5 0.0368
ENSG00000119938 PPP1R3C − 0.6 3.2 × 10−5 0.0375
ENSG00000135299 ANKRD6 − 0.4 4.5 × 10−5 0.0497
Differential expression analysis based on the RNA-Sequencing data. Log2 fold changes are given for the comparison smokers against never smokers
aDifferentially methylated in our EWAS with q < 0.05
Richter et al. Clinical Epigenetics          (2019) 11:105 Page 10 of 18
two significant CpGs mapping to AHRR and CYP1B1,
and another CpG 6 kb downstream of CYP1A2.
We consider the association of the non-coding RNA
LINC00673 as another interesting finding. This lncRNA
was significantly hypomethylated in smokers in our
study at three individual CpGs. This gene was shown to
be upregulated in tongue squamous cell carcinoma [38].
Differential methylation of AHRR, CYP1B1,
and LINC00673 was shown before in buccal cells of
smokers [22]. Increased expression of CYP1B1 by
cigarette smoke was shown in vivo in buccal cells after
smoke stimulation [39], in bronchial airway epithelial
cells from smokers [40] and in vitro in A549 lung adeno-
carcinoma cells [23]. CYP1B1-AS1 was also shown to be
upregulated in vitro by CSE exposure in A549 cells [23].
We could validate these findings in our differential expres-
sion analysis, showing a significant upregulation of
CYP1B1, and additionally of CYP1A1 in the masticatory
mucosa of smokers and a CSE-induced upregulation of
CYP1B1 and CYP1B1-AS in vitro. Likewise, pathway ana-
lysis of differentially expressed genes revealed a significant
upregulation of genes involved in the Metabolism of Xe-
nobiotics by Cytochrome P450-KEGG pathway. Smoking
is a widespread risk factor for periodontitis, a common in-
flammatory disease of the supporting tissues of the oral
cavity, which is characterised by severe inflammation of
the gingiva and irreversible bone degradation leading to
tooth loss. With the data provided by this study, we add
evidence to the significance of smoking on differential
DNA methylation of cytochrome-P450-mediated AhR-
Table 6 Results from the pathway analyses for differentially expressed genes
Pathway Identifier Class p value q value
Reactome database
The Citric Acid Cycle and Respiratory Electron Transport R-HSA-1428517 Metabolism (electron transport) 1.4 × 10−5 0.009
tRNA Aminoacetylation R-HSA-379724 Metabolism of proteins 1.1 × 10−4 0.019
Assembly of the pre-Replicative Complex R-HSA-68867 DNA replication 1.3 × 10−4 0.019
M-G1-Transition NA Cell cycle 1.4 × 10−4 0.019
Cytosolic tRNA Aminoacylation R-HSA-379716 Metabolism of proteins 1.7 × 10−4 0.019
HIV-Infection R-HSA-162906 Disease 2.1 × 10−4 0.019
Host Interactions of HIV Factors R-HSA-162909 Disease 2.1 × 10−4 0.019
Cell Cycle Checkpoints R-HSA-69620 Cell Cycle 3.4 × 10−4 0.021
Destabilisation of mRNA by AUF1 (hnRNP D0) R-HSA-450580 Metabolism of RNA 3.5 × 10−4 0.021
Respiratory electron transport, ATP synthesis by
chemiosmotic coupling, and heat production by
uncoupling proteins
R-HSA-163200 Metabolism (electron transport) 3.7 × 10−4 0.021
CDT1 association with the CDC6:ORC:origin complex R-HSA-68827 DNA replication 3.7 × 10−4 0.021
Genes involved in APC/C:Cdc20 mediated degradation of
mitotic proteins
R-HSA-176409 Cell cycle 5.4 × 10−4 0.026
Orc1 removal from chromatin R-HSA-68949 Cell cycle, DNA replication 5.7 × 10−4 0.026
Regulation of mitotic cell cycle R-HSA-453276 Cell cycle 6.0 × 10−4 0.026
Respiratory electron transport R-HSA-611105 Metabolism (electron transport) 6.0 × 10−4 0.026
G1/S Transition R-HSA-69206 Cell cycle 7.3 × 10−4 0.029
Regulation of ornithine decarboxylase (ODC) R-HSA-350562 Metabolism 9.2 × 10−4 0.033
CDK-mediated phosphorylation and removal Cdc6 R-HSA-69017 Cell cycle, DNA replication 9.5 × 10−4 0.033
Autodegradation of the E3 ubiquitin ligase COP1 R-HSA-349425 Cell cycle 9.8 × 10−4 0.033
APC/C:Cdh1 mediated degradation of Cdc20 and other
APC/C:Cdh1 targeted proteins in late mitosis/early G1
R-HSA-174178 Cell cycle 1.2 × 10−3 0.038
Metabolism of RNA R-HSA-8953854 Metabolism of RNA 1.3 × 10−3 0.038
SCF-beta-TrCP mediated degradation of Emi1 R-HSA-174113 Cell cycle 1.4 × 10−3 0.039
Mitotic G1-G1/S phases R-HSA-453279 Cell cycle 1.4 × 10−3 0.040
Mitotic M-M/G1 phases R-HSA-453274 Cell cycle 1.5 × 10−3 0.040
KEGG database
Aminoacyl tRNA Biosynthesis hsa00970 Translation 1.9 × 10−4 0.034
Metabolism of Xenobiotics by Cytochrome P450 rn00980 Metabolism/xenobiotics biodegradation 3.7 × 10−4 0.034
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pathway, a pathway that is involved in smoke-mediated
bone degradation [37].
Apart from the upregulation of the Cytochrome P450-
related pathway, Reactome pathway analysis of differen-
tially expressed genes found 58% (14 out of 24) altered
pathways relating to the classes DNA replication or cell
cycle function, suggesting a connection of smoking and
tumorigenesis.
Our data did not suggest a global correlation of the re-
sults from the differential methylation analysis with the
differential expression analysis. However, we note that
the majority of effect sizes in smoking EWAS are not
large, with 12.5% hypomethylation in smokers for AHRR
in our study. Therefore, the identification of subtle
changes in expression caused by the methylation differ-
ences detected in EWAS requires very large sample
sizes, even if assumed that the relationship between
methylation and expression is linear. When accounting
for other regulatory mechanisms that disturb this
hypothesised linearity, the detection of a direct relation-
ship between changes in methylation patterns and
changes in expression patterns becomes even more
Fig. 6 Gene expression of CYP1B1 and CYP1B1-AS is significantly increased by cigarette smoke extract in vitro. Primary gingival fibroblast cell lines
were cultured from three independent ex vivo biopsies (FB1–3) and treated for 6 h with cigarette smoke extract (CSE), labelled as “+”. Control cell
lines without CSE treatment are labelled as “−”. qRT-PCR data were obtained from five treatments with CSE. Significant upregulation upon CSE
treatment were observed for CYP1B1 (padj = 0.019) and CYP1B1-AS (padj = 0.023). P values are Bonferroni-adjusted for two independent tests
Table 7 Correlation of differential methylation with differences in transcript levels
Gene p value (DE) q value (DE) log2FC Best CpG Chr Position in bp (hg19a) Add. CpGs p value (DM)b q value (DM) Δβ/10 SPY
CYP1B1 2.2 × 10−14 1.3 × 10−10 2.94 cg01584760 2 38,296,474 6 3.8 × 10−10 3.1 × 10−4 − 0.046
SLC7A5 1.1 × 10−4 6.5 × 10−2 0.62 cg10099957 16 87,869,757 2 9.6 × 10−6 7.1 × 10−2 − 0.060
LAMA3c 0.025 0.64 − 0.20 cg16113793 18 21,451,607 1 1.5 × 10−6 4.0 × 10−2 − 0.027
EDC3 0.031 0.65 0.39 cg17181940 15 74,948,075 1 5.6 × 10−6 5.9 × 10−2 − 0.054
Genes nominally significant in the differential expression (DE) analysis that correspond to those CpGs that were associated with smoke pack years (SPY) with q <
0.15 in the differential methylation (DM) analysis and that lie within genetic regions previously reported to be differentially methylated in buccals [22]. EDC3 was
additionally reported to be differentially methylated in blood [32]
aNCBI build GRCh37
bp values are from the analysis of covariance (ANCOVA) with adjustment by age, sex and batch. DE differential expression, Log2FC log2fold change, Chr
chromosome, bp basepairs, Add. CpGs additional CpGs significant with q < 0.15 at this locus, DM differential methylation, SPY smoke pack years
cEffect sizes for DE and DM are contradictory
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difficult. Accordingly, EWAS that identified a large correl-
ation of significant methylation with transcription differ-
ences are rare, and this despite the fact that
hypomethylation is functionally associated with increased
gene expression. However, we are aware of a large study
that addressed the effects of smoking on methylation and
transcription in 730 blood samples, which identified 254
CpGs showing significant correlation of differential
methylation with expression values of nearby transcripts
[13]. We presume that our non-finding of a global correl-
ation is probably due to the lack of statistical power of the
comparably small sample size. When filtering our expres-
sion data for genes with multiple associated CpGs and
taking into account knowledge on previously published
differentially methylated CpGs, in addition to CYP1B1, we
identified two further genes, SLC7A5 and EDC3, that
showed consistent effect sizes for differential methylation
and differential expression, and which were supported by
smoking EWAS on buccal cells or blood. Variants within
EDC3 have been reported in a large meta-analysis on caf-
feine intake, together with AHR, CYP1A1 and CYP1A2
[41]. EDC3 is located 25 kb upstream of CYP1A1 and ~
55 kb upstream of CYP1A2, which also harboured an as-
sociated CpG 6 kb upstream in our EWAS. Taken to-
gether, our results point towards an important role of
differential methylation of several genes of the CYP-gene
cluster on chromosome 15 to regulate the AhR-pathway
in the masticatory mucosa of smokers.
In the comparison of CYP1B1 methylation patterns of
our never smokers data with the OSCC samples, all five sig-
nificant CpGs were hypomethylated in our EWAS but in
the OSCC data, CYP1B1 showed global hypermethylation
(16 out of 17 significant CpGs). For AHRR, findings are less
clear because none of our CpG was analysed on the 450k
chip used for the OSCC samples. Likewise, in 51 OSCC
samples from various extraction sites (e.g. buccal mucosa,
floor of mouth, lip, palate), significant downregulation of
CYP1B1 transcript levels was reported [42]. This contra-
dicts the observation that CYP1B1 was overexpressed in
many cancers [43]. As suggested earlier [22, 23], our obser-
vations may indicate that demethylation and upregulation
of CYP1B1 in the oral mucosal tissues of smokers is not
causal for the development of cancer, but in contrast, part
of the normal cellular detoxification. In oral cancer, these
pathways might be misregulated, which in turn would lead
to impaired regulation of xenobiotic metabolism. However,
these results contradict findings from other cancer types,
where CYP1B1 is overexpressed and serves as a tumour
marker [44]. It needs to be emphasised that a major limi-
tation of the OSCC dataset is that extraction sites were
not specified. Cell compositions vary among different re-
gions of the oral cavity [45], which is also suggested by the
results of our cell type deconvolution analysis, and which
could account for a stratification of results. As OSCC and
other oral tissue samples from TCGA most likely have a
heterogeneous cellular background originating from di-
verse tissue extraction sites, they might not be a perfect
data source for a straightforward identification of differen-
tial methylation patterns. To investigate cell type-specific
and disease-relevant methylation patterns in specific parts
of the oral mucosa, further cell type deconvolution studies
from different extraction sites and cell types of the oral
mucosa can improve future analyses. The main limitation
of our EWAS was the small sample size. Yet, our samples
Table 8 Associations of smoking and cancer with differential methylation of AHRR and CYP1B1
CpG Chr Position in
bp (hg19a)
Association with SPY (EWAS
samples)
Association with smoking status
(EWAS samples)
Association with OSCC
Δβ/10 SPY pnom q Δβ pnom q Δβ pnom padj
CYP1B1 cg01584760b 2 38,296,474 − 0.046 3.8 × 10−10 3.1 × 10−4 − 0.045 1.0 × 10−4 0.853 Not analysed
cg02162897 2 38,300,537 − 0.11 1.2 × 10−7 0.014 − 0.183 5.5 × 10−8 0.022 0.197 4.7 × 10−6 6.1 × 10−4
cg20408276 2 38,300,586 − 0.108 1.1 × 10−7 0.014 − 0.176 3.6 × 10−7 0.04 Not analysed
cg00565882 2 38,300,707 − 0.041 1.7 × 10−6 0.042 − 0.044 0.005 1 0.16 8.6 × 10−7 1.1 × 10−4
cg01410359 2 38,302,230 − 0.037 3.4 × 10−6 0.047 − 0.032 0.023 1 0.177 8.8 × 10−7 1.1 × 10−4
AHRR cg04551776 5 393,366 − 0.007 4.3 × 10−1 0.97 − 0.011 0.43 1 0.149 2.7 × 10−5 3.5 × 10−3
cg06036945 5 394,869 − 0.067 1.0 × 10−4 0.18 − 0.125 3.7 × 10−7 0.04 Not analysed
cg04066994c 5 394,891 − 0.041 8.2 × 10−6 0.067 − 0.083 5.9 × 10−10 4.7 × 10−4 Not analysed
cg25648203 5 395,444 − 0.007 0.42 0.99 − 0.012 0.37 1 − 0.081 9.7 × 10−3 1
Shown are the results for all CpGs within CYP1B1 and AHRR that were significantly associated with SPY levels or smoking status in our EWAS. We compared AHRR
and CYP1B1 methylation levels in 16 oral squamous cell carcinoma (OSCC) samples from TCGA to our healthy never smoker samples. Differential methylation
analysis was performed using an ANCOVA adjusting for sex and unknown variation. The CpGs cg01584760, cg20408276, cg06036945 and cg04066994 were not
covered by the 450k analysis of the OSCC samples. For AHRR, we added the results for cg04551776 and cg25648203, which flanked our EWAS-CpGs with a
distance of 1503 bp and 553 bp, respectively, albeit these CpGs were not associated in our EWAS
aNCBI build GRCh37
bTop significant CpG in the differential methylation analysis with SPY
cTop significant CpG in the differential methylation analysis with smoking status. Chr chromosome, bp basepairs, SPY smoke pack years, Padj Bonferroni-adjusted
for 130 tests
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allowed the detection of the most significant tobacco
smoke-related differentially methylated loci, which indi-
cates the power of this homogeneously collected sample
set.
Conclusion
The current study adds evidence to previous EWAS that
reported significant hypomethylation of AHRR and
CYP1B1 in buccal and airway epithelium of smokers.
We could show increased expression of CYP1B1 and
CYP1B1-AS in the masticatory mucosa of smokers
as compared to never smokers and validated upregula-
tion of these genes by cigarette smoke in vivo and in
vitro. We conclude that hypomethylation of AHRR and
CYP1B1 is an important regulatory mechanism of xeno-
biotic metabolism of the masticatory mucosa in response
to tobacco smoke exposure.
Methods
Study sample
A total of 39 healthy smokers and never smokers, i.e.
free of systemic disease, and all of European descent,
were enrolled in this study, which was conducted in ac-
cordance with the principles of Good Clinical Practice
and approved by the Independent Ethics Committee of
each participating University Hospital. Written informed
consent was obtained from all subjects according to the
Declaration of Helsinki. All study participants completed
a detailed questionnaire to provide general personal in-
formation (e.g. sex, age, geographical and family des-
cent), information on the general and oral health and
smoking habits (current, former, never smoker and
amount of smoking in cigarette packs per day and dur-
ation of smoking in years). We calculated smoking pack
year (SPY) values by multiplying the number of
smoked cigarette packs per day by the number of
years smoked. Fifty percent of the smokers had > 10
SPY, and 50% had between two and ten SPY. The
mean age in smokers was 38 years and 35 years in
never smokers. All individuals underwent periodontal
examination prior to tissue extraction to exclude the
presence of PD. Only individuals with a periodontal
screening index (PSI) < 2 were included, indicating the
absence of severe oral inflammation.
Collection of ex-vivo tissue samples from the masticatory
oral mucosa
Solid tissue samples from the oral masticatory mucosa
were collected at a defined site from the hard palate
adjacent to the 4th and 5th tooth by the use of a tis-
sue puncher with 3 mm diameter and a depth of ap-
proximately 1 mm (for an illustration of the area of
tissue sampling, see Additional file 7: Figure S1). We
consider this site also representative for the gingival
mucosa (i.e. often inflamed in periodontitis) because
the gingival masticatory mucosa and the masticatory
mucosa of the hard palate share the same histological
cellular structures (Stratum basale, Str. spinosum, Str.
granulosum, Str. corneum) and therefore the same
cell types (Additional file 7: Figure S2). Likewise, indi-
cating similar states of cellular differentiation, tissue
collection at the specified sampling area is a common
approach during periodontal surgery when free gin-
gival grafts are excised and transplanted to other mu-
cosal areas in the oral cavity. To stabilise DNA and
RNA, the biopsies were stored in the AllProtect re-
agent (Qiagen, Hilden, Germany) immediately after
punching, stored at 4 °C for 24 h, and subsequently
transferred to − 20 °C.
DNA and RNA extraction
The conserved tissue samples were manually broken up
into small pieces with a scalpel and subsequently homoge-
nised using the automated mixer mill MM 400 (Retsch,
Haan, Germany) using frozen beads (3 mm, Retsch) for
90 s at 30 Hz. Subsequently, DNA and RNA was extracted
simultaneously using the AllPrep DNA/RNA/miRNA
Universal Kit (Qiagen, Hilden, Germany), ensuring the
same cellular background of DNA and RNA for subse-
quent comparison of DNA-methylation and RNA-
expression. Integrity of DNA and RNA was subsequently
verified with a 2% agarose gel electrophoresis. Concentra-
tions were measured using the Multiskan GO Microplate
Spectrophotometer (Fisher Scientific, Hampton, USA).
DNA and RNA samples were stored at − 80 °C.
Bisulfite conversion and hybridisation to the Infinium
MethylationEPIC BeadChips
Five hundred nanograms DNA per sample was bisulfite
converted with the EZ-96 DNA Methylation Kit (Zymo
Research, Irvine, USA) and hybridised to the Infinium
DNA MethylationEPIC BeadChip (Illumina, San Diego,
USA) on an iScan Microarray Scanner (Illumina) at the
Institute for Clinical Molecular Biology, Christian-
Albrechts-University Kiel, Germany.
Differential DNA methylation analysis
For analysis and quality control, the R environment
(Version 3.5.1) and the R package minfi (1.26.2) [46]
were used, including the R package limma (Version
3.36.5) for the differential methylation analysis [47]. The
Red/Green channel of the array were converted into one
methylation signal without any normalisation. Using the
function plotQC, we estimated sample-specific quality
control (QC) and did not remove any sample. The QC
criteria for probes were filtering of probes with median
detection p values > 0.05, probes that lay within 5 base-
pairs (bp) of a single nucleotide polymorphism (SNP)
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with > 5% minor allele frequency, probes on the sex
chromosomes and cross-reactive probes using the R
package maxprobes (https://rdrr.io/github/markgene/
maxprobes) according to Pidsley et al. [48] and McCart-
ney et al. [49]. In total, 802,254 probes complied with
the QC criteria and were included in the analysis.
Methylation status was estimated according to the fluor-
escent intensity ratio, as any value between β = 0
(unmethylated) and 1 (completely methylated), and log2-
transformed into M values, which are considered a more
statistically valid estimator [50]. Corresponding effect
sizes are, for a better biological understanding, given as
Δβ, unless otherwise stated. After quality control, we
performed a functional normalisation using the prepro-
cessFunnorm function in minfi [51]. To identify CpGs
correlating significantly with SPY, an analysis of covari-
ance (ANCOVA) was performed for SPY as a continuous
variable with adjustment by age as a continuous variable
and sex as a categorical variable. We used SPY in this
model to account for the cumulative risk exposure con-
ferred by long-term smoking as suggested by Teschen-
dorff et al. 2015 [22]. We additionally investigated
differential methylation correlating with smoking status
by performing an ANCOVA with the covariates age and
sex. In both analyses, we additionally adjusted for tech-
nical variation, i.e. slide and position on slide, by using
Combat and the R package BatchQc [52]. Correction for
multiple testing was performed using the method by
Benjamini & Hochberg [53]. CpGs were annotated to
genes according to GRCh37/hg19 as provided in the
MethylationEPIC BeadChip manifest.
Cell type deconvolution of EWAS samples
To identify the presence of non-epithelial cells in our
samples of oral mucosa, we used the EpiDISH algorithm
(Version 3.9) [54], applying the centEpiFibIC.m.rda ref-
erence dataset on our beta-values, which includes cen-
troids for epithelial cells, fibroblasts and immune cells.
RNA-sequencing
To validate the effects of the observed methylation
differences between smokers and never smokers on
gene expression in the oral mucosa, we performed
RNA-sequencing (RNA-Seq) of the same samples that
were used in the EWAS. This ensured a homoge-
neous genetic and cellular background of the methy-
lation and expression analysis. The total mRNA of 38
biopsy samples that passed QC for RNA-Seq (>
600 ng of total RNA, RIN > 7) was sequenced with a
coverage of 16 million 50 bp single-end reads per
sample. One RNA-sample was discarded due to low
amounts of RNA. In brief, the library preparation was
performed with 600 ng RNA using the TruSeq
Stranded mRNA Kit (Illumina). RNA-Seq was per-
formed on a HiSeq3000 (Illumina) at the Institute for
Clinical Molecular Biology of the Christian-Albrechts-
University Kiel, Germany.
Differential expression analysis
RNA-seq samples were mapped to the transcriptome
(Ensembl 96, GRCh38) using the transcript abundance
quantification method Salmon [55]. Salmon estimates
abundances without aligning reads. The transcript level
estimates were then summarised for the gene level and
imported into R using the package tximport [56]. Subse-
quently, the imported data was analysed for differential
expression between smokers and never smokers using
DESeq2 [57]. Genes with ≤ 2 counts in all samples com-
bined were not considered in the analyses. To identify
genes that show substantial evidence for a correlation of
differential expression with differential methylation in
smokers, we applied the following steps: (1) filtering of
all differentially expressed transcripts with unadjusted
p < 0.05; (2) filtering of transcripts with more than one
CpG associated with q < 0.15 with SPY; (3) filtering of
transcripts that were previously reported in a large
EWAS on buccal swabs [22] or in a systematic review
on EWAS on blood [32].
Gene set enrichment analysis of differentially expressed
genes
Gene sets of KEGG (n = 186) and Reactome (n = 674)
were gathered from the Broad Institute Molecular Signa-
tures Database (MSigDB [58, 59]). Together with the
log2FoldChanges of the differential expression analysis,
we performed an enrichment analysis using the R pack-
age gage [60]. Gene sets with q value < 0.05 were consid-
ered as being significantly enriched.
Preparation of cigarette smoke extract and RNA
extraction of cultured cells
Cigarette smoke extraction system and cigarette smoke
extract (CSE) were prepared as described in [61]. CSE
was prepared from Roth-Händle no filters cigarettes
(Reemtsma, Hamburg, Germany). Smoke of three ciga-
rettes was filtered using a 0.2-μM sterile filter and ex-
tracted into 10 mL cell culture medium. The CSE-
containing medium was directly added to the cells
(3 mL per well).
CSE stimulation of primary gingival fibroblasts
For CSE stimulation, solid ex vivo biopsies of the masti-
catory oral mucosa of the hard palate were taken from
three additional participants with 3 mm tissue punchers.
Biopsies were dissected enzymatically to separate the epi-
thelial cells from the fibroblasts by overnight incubation
in 5 mg/mL dispase II (Sigma Aldrich) diluted in cell
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growth medium (DMEM, 1% Pen/Strep) at 4 °C. The pri-
mary gingival fibroblast cells (pGFs) were subsequently
cultured in cell growth medium (DMEM, 1% Amphoteri-
cin B, 1% Pen/Strep, 1% non-essential amino acids). Prior
to CSE stimulation, the pGFs (passage 3–4) were seeded
in 6-well tissue culture plates (TPP Techno Plastic Prod-
ucts, Trasadingen, Switzerland) 24 h before stimulation
(2.2 × 105 cells per well). The CSE was freshly prepared at
the day of stimulation. CSE induction was performed for
6 h in three biological replicates (each with five technical
replicates) of pGFs, with aliquots of the same CSE. Three
millilitre medium without CSE was added to the control
cell plates (five technical replicates for each of the three
donors). After 6 h of CSE incubation, the cells were
washed twice with PBS. Cell disruption and total RNA ex-
traction was carried out using the RNeasy Mini Kit (Qia-
gen) according to the manufacturer’s instructions.
cDNA synthesis and qRT-PCR
To test differential expression in primary gingival fibro-
blasts upon CSE-stimulation, we performed quantitative
reverse transcription polymerase chain reaction (qRT-
PCR) for CYP1B1 and CYP1B1-AS. qRT-PCR was
performed with an amount of 500 ng of total RNA of
CSE-stimulated cells using the High-Capacity cDNA Re-
verse Transcription Kit and oligo-(dT)-primers (Thermo
Fisher Scientific, Waltham, USA) in accordance with the
manufacturer’s guidelines, using oligo-(dT)- and dNTP-
primers instead of random primers. Control PCR
reactions contained water instead of cDNA. qRT-PCR ex-
periments were performed using the CFX Connect System
(Bio-Rad, Hercules, USA) in combination with SYBR Se-
lect Master Mix (Thermo Fisher Scientific) according to
the manufacturer’s instructions. The gene expression
levels were normalised to the mRNA expression of
GAPDH, and relative expression was calculated using the
mathematical model delta-delta ct (GraphPad Prism Soft-
ware/R). Primers were manufactured (metabion GmbH,
Planegg/Steinkirchen, Germany) with the following se-
quences: CYP1B1 (forward: GAC GAC CCC GAG TTC
CGT GA; reverse: AGC CAG GGC ATC ACG TCC AC)
and CYP1B1-AS (forward: AGC CCT GAA AGA TGA
ACA GTG GT; reverse: GGC ATG CCC ATT TCT TCC
ACA). Because the lncRNA CYP1B1-AS1 was not covered
by mRNA-Sequencing, we analysed expression in our ex-
vivo biopsies from the EWAS and 17 additional biopsies
that were collected as described above with qRT-PCR. In
total, CYP1B1-AS-expression of 32 smokers and 37 never
smokers was analysed.
Cell type deconvolution and differential methylation
analysis of OSCC samples
To identify a putative role of genes that showed differen-
tial methylation in oral mucosa of smokers in cancer-
development, we analysed data from The Cancer Gen-
ome Atlas (TCGA) [62]. We downloaded Illumina 450k
methylation bead chip data from 16 samples of oral
squamous cell carcinoma (OSCC) of keratinized oral
mucosa (sites specified as “palate” or “gums”; i.e., Hard
Palate, Upper Gum, Lower Gum and Gum NOS in the
TCGA). To account for cell type-specific methylation,
we performed the cell type deconvolution analyses on
the 450k OSCC data as described above. We then per-
formed an ANCOVA for all 130 CpGs that were anno-
tated on the Illumina 450k array to the genetic regions
of CYP1B1 and AHRR with sex as a covariate and adjust-
ing for technical variation using the R package sva [63]
to compare OSCC samples to the healthy never smokers
from the EWAS.
Additional files
Additional file 1: CpGs from the literature associated with SPY in our
data. Results are shown for the ANCOVA with SPY for all CpGs with q <
0.15 in our EWAS that map to genes harbouring a significant CpG in an
EWAS on buccal swabs [22] or were reported as replicated in at least two
independent EWAS on blood [32]. (XLSX 47 kb)
Additional file 2: Results of the EpiDISH cell type deconvolution.
Estimates for the different cell type fractions are given each for the EWAS
samples and the OSCC samples, each also additionally divided into the
subsets smokers and non-smokers. (XLSX 17 kb)
Additional file 3: Median TPM values from RNA-Sequencing. Transcripts
were ranked according to their median TPM value in the EWAS samples,
with the highest expressed genes on top. (XLSX 1299 kb)
Additional file 4: Results from the KEGG and Reactome Pathway
Analyses of Differentially Expressed Genes. (XLSX 76 kb)
Additional file 5: Correlation of associated CpGs with association of
transcripts. Shown are all CpGs with q < 0.15 that map to genes that
were differentially expressed in smokers with a nominal p value of < 0.05.
(XLSX 14 kb)
Additional file 6: Results from the ANCOVA of OSCC samples in AHRR
and CYP1B1. Listed are all CpGs within the genetic regions of AHRR and
CYP1B1 (n = 202) to indicate absence of CpGs in the 450 k analysis of
OSCC. CpGs passing the adjusted significance threshold are marked in
red. (XLSX 8961 kb)
Additional file 7: Figure S1. Area of tissue sampling. The tissue
samples were collected from the hard palate directly adjacent to the 4th
and 5th tooth by the use of a tissue puncher (3 mm diameter). Figure
S2. Histological features of the masticatory mucosa of the gingiva and
the hard palate. The mucosa of both sites is characterised by the four
layered orthokeratinised stratified squamous epithelium, overlaying the
lamina propria. The lamina propria contains closely packed bundles of
collagen fibres enabling the mucosa to resist heavy loading. The cells in
the upper keratin layer have lost their nuclei. Because the function and
appearance of the cells and cell layers from both extraction sites are
similar, it is the broad agreement of the periodontologists participating in
this study that both sites are comparable and are likely to share similar
methylation patterns under normal conditions. (DOCX 1137 kb)
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